The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Impact of Oxypurinol in Patients With Symptomatic Heart Failure
Open accessAbstract
Objectives This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy.Background Increased XO activity may contribute to heart failure pathophysiology.Methods Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life.Results The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by approximately 2 mg/dl (p < 0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA <9.5 mg/dl exhibited a trend towards worsening. In addition, SUA reduction to oxypurinol correlated with favorable clinical response. Within the entire oxypurinol patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA compared with patients who worsened (-2.3 +/- 2.1 mg/dl vs. -1.0 +/- 1.9 mg/dl, p = 0.0006). In placebo patients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.Conclusions Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. However, post-hoc analysis suggests that benefits occur in patients with elevated SUA in a manner correlating with the degree of SUA reduction. Serum uric acid may serve as a valuable biomarker to target XO inhibition in heart failure. (Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite these initial results, subsequent trials with larger number of patients have failed to report substantial positive effects as compared with the placebo groups (361, 405), although the meta-analysis of available studies indicates some improvement of cardiovascular function (430).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [405]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berry, C. E., & Hare, J. M. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055913 · Cited by 925
Self-citationAnker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C. H., Cicoira, M., Shamim, W., Kemp, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000065637.10517.a0 · Cited by 593
Casella, G., Carr, E., Davies, J. I., Belch, J. J. F., & Struthers, A. D. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 574
Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity
Watanabe, S., Kang, D., Feng, L., Nakagawa, T., Kanellis, J., Lan, H. Y., Mazzali, M., & Johnson, R. J. (2002) · Hypertension · doi:10.1161/01.hyp.0000028589.66335.aa · Cited by 562
Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure
Landmesser, U., Spiekermann, S., Dikalov, S., Tatge, H., Wilke, R., Kohler, C., Harrison, D. G., Hornig, B., & Drexler, H. (2002) · Circulation · doi:10.1161/01.cir.0000041431.57222.af · Cited by 525
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
Self-citationPacker, M. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.25652 · Cited by 397
Spiekermann, S., Landmesser, U., Dikalov, S., Bredt, M., Gamez, G., Tatge, H., Reepschläger, N., Hornig, B., Drexler, H., & Harrison, D. G. (2003) · Circulation · doi:10.1161/01.cir.0000056762.69302.46 · Cited by 298
Landmesser, U., Spiekermann, S., Preuss, C., Sorrentino, S., Fischer, D., Manes, C., Mueller, M., & Drexler, H. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000258415.32883.bf · Cited by 210
Cited by
Sorted by citations
Items 201–300 of 393
Inflammation and Heart Failure: Searching for the Enemy—Reaching the Entelechy
PARASKEVAIDIS, I. A., Farmakis, D. T., Papingiotis, G., & Tsougos, E. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10010019 · Cited by 27
Xanthine oxidase inhibition for the treatment of stroke disease: a novel therapeutic approach
Higgins, P., Ferguson, L. D., & Walters, M. R. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.29 · Cited by 26
Heart failure in the elderly: advances and challenges
Jugdutt, B. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.36 · Cited by 26
Gladden, J. D., Zelickson, B. R., Guichard, J. L., Ahmed, M. I., Yancey, D. M., Ballinger, S. W., Shanmugam, M., Babu, G. J., Johnson, M. S., Darley-Usmar, V. M., et al. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00007.2013 · Cited by 25
Oxidative Stress and Cell Death in Cardiovascular Disease
Marı́n-Garcı́a, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404599-6.00014-7 · Cited by 26
Kessler, E. L., Oerlemans, M. I. F. J., van den Hoogen, P., Yap, C., Sluijter, J. P. G., & de Jager, S. C. A. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10026-3 · Cited by 27
Cardiovascular diseases crossroads: cGAS-STING signaling and disease progression
Khan, M. S., Khan, S. U., Khan, S. U., Suleman, M., Ahmad, R. U. S., Khan, M. U., Tayyeb, J. Z., Crovella, S., Harlina, P. W., & Saeed, S. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102189 · Cited by 26
Desideri, G., Rajzer, M. W., Gerritsen, M., Nurmohamed, M. T., Giannattasio, C., Tausche, A., & Borghi, C. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa144 · Cited by 23
Physiological regulation of cardiac contractility by endogenous reactive oxygen species
Perjés, Á., Kubin, A., Kónyi, A., Szabados, S., Cziráki, A., Skoumal, R., Ruskoaho, H. J., & Szokodi, I. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02391.x · Cited by 31
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 23
Baldasseroni, S., Urso, R., Maggioni, A. P., Orso, F., Fabbri, G., Marchionni, N., & Tavazzi, L. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.08.007 · Cited by 21
Traynham, C. J., Roof, S. R., Wang, H., Prosak, R. A., Tang, L., Viatchenko‐Karpinski, S., Ho, H., Racoma, I. O., Catalano, D. J., Huang, X. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052005 · Cited by 21
Liu, C., Zhao, Q., Zhen, Y., Gao, Y., Li, T. X., Wang, L., Ji, L., Liu, G., Ji, Z., & Liu, K. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.008 · Cited by 21
Zhou, H., Xu, T., Liu, S.-R., Bai, Y., Huang, X.-Y., Zhan, Q., Zeng, Q., & Xu, D. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.01.001 · Cited by 21
Gingles, C., Symon, R., Gandy, S. J., Struthers, A. D., Houston, J. G., MacDonald, T. M., Lang, C. C., Donnan, P. T., & Casella, G. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002189 · Cited by 21
Serum Uric Acid Level and Subclinical Left Ventricular Dysfunction: A Community-Based Cohort Study
Nakanishi, K., Daimon, M., Yoshida, Y., Ishiwata, J., Sawada, N., Hirokawa, M., Kaneko, H., Nakao, T., Mizuno, Y., Morita, H., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12691 · Cited by 21
Opie, L. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.072 · Cited by 19
Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?
Gelosa, P., Castiglioni, L., Camera, M., & Sironi, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113894 · Cited by 19
Xanthine oxidase inhibition for cardiovascular disease prevention
Tanaka, A., & Node, K. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01778-0 · Cited by 20
Plummer, B. N., Liu, H., Wan, X., Deschênes, I., & Laurita, K. R. (2014) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.114.001789 · Cited by 20
Reddy, Y. N. V., Borlaug, B. A., O’Connor, C. M., & Gersh, B. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz364 · Cited by 22
Cardiac Energetic Impairment in Heart Disease and the Potential Role of Metabolic Modulators
Singh, S., Schwarz, K., Horowitz, J. D., & Frenneaux, M. P. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000221 · Cited by 22
Nitroso-Redox Imbalance Affects Cardiac Structure and Function
Karantalis, V., Schulman, I. H., & Hare, J. M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.016 · Cited by 20
Self-citationStone, P. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.072 · Cited by 20
Campbell, R. T., Willox, G., Jhund, P. S., Hawkins, N. M., Huang, F., Petrie, M. C., & McMurray, J. J. V. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002842 · Cited by 19
Marcinkiewicz-Siemion, M., Kaminski, M., Ciborowski, M., Ptaszynska-Kopczynska, K., Szpakowicz, A., Lisowska, A., Jasiewicz, M., Tarasiuk, E., Kretowski, A. J., Sobkowicz, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56889-8 · Cited by 19
Physiological regulation of cardiac contractility by endogenous reactive oxygen species
Perjés, Á., Kubin, A., Kónyi, A., Szabados, S., Cziráki, A., Skoumal, R., Ruskoaho, H. J., & Szokodi, I. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02391.x · Cited by 19
Allopurinol reduces antigen-specific and polyclonal activation of human T cells
Pérez‐Mazliah, D., Albareda, M. C., Alvarez, M., Lococo, B., Bertocchi, G. L., Petti, M. A., Viotti, R. J., & Laucella, S. A. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00295 · Cited by 19
The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) Trial
Casella, G., & Struthers, A. D. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.076 · Cited by 19
Unraveling the relationship between serum uric acid levels and cardiovascular risk
Carluccio, E., Coiro, S., & Ambrosio, G. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.11.035 · Cited by 19
Abnormal Ca 2+ Cycling in Failing Ventricular Myocytes: Role of NOS1-Mediated Nitroso-Redox Balance
Ziolo, M. T., & Houser, S. R. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5873 · Cited by 18
Cardiovascular Safety of Urate Lowering Therapies
Kang, E. H., & Kim, S. C. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0843-8 · Cited by 18
The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide
O’Meara, E., Thibodeau-Jarry, N., Ducharme, A., & Rouleau, J. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.09.032 · Cited by 16
Bonsu, K. O., Owusu, I. K., Buabeng, K. O., Reidpath, D. D., & Kadirvelu, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s106065 · Cited by 16
on behalf of the SMILE Working Project, Borghi, C., Omboni, S., Reggiardo, G., Bacchelli, S., Esposti, D. D., & Ambrosioni, E. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0800-x · Cited by 16
Reactive Oxygen/Nitrogen Species and the Myocardial Cell Homeostasis: An Ambiguous Relationship
Kuster, G. M., Häuselmann, S. P., Rosc-Schlüter, B. I., Lorenz, V., & Pfister, O. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3464 · Cited by 15
Documento de consenso para la detección y manejo de la enfermedad renal crónica
Martínez‐Castelao, A., Górriz, J. L., Bover, J., la Morena, J. S.-D., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., et al. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.06.003 · Cited by 17
Frontiers of Therapy for Patients With Heart Failure
Liu, S. S., Monti, J., Kargbo, H. M., Athar, M. W., & Parakh, K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.033 · Cited by 16
The risk of atrial fibrillation in patients with gout: a nationwide population-based study
Kuo, Y., Tsai, T., Chang, H.-P., Chua, S. O., Chung, S., Yang, C., Lin, C.-J., Wu, C.-J., & Hang, C. (2016) · Scientific Reports · doi:10.1038/srep32220 · Cited by 15
In-Hospital Serum Uric Acid Change Predicts Adverse Outcome in Patients With Heart Failure
Yamamoto, H., Nagatomo, Y., Mahara, K., & Yoshikawa, T. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.07.002 · Cited by 15
Xu, H., Liu, Y., Meng, L., Wang, L., & Liu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639392 · Cited by 15
Ácido úrico: una molécula con acciones paradójicas en la insuficiencia cardiaca
Alcaíno, H., Greig, D. P., Castro, P., Verdejo, H., Mellado, R., Garcı́a, L., Dı́az-Araya, G., Quiroga, C., Chiong, M., & Lavandero, S. (2011) · Revista médica de Chile · doi:10.4067/s0034-98872011000400014 · Cited by 15
Ramandi, M. M. A., Maleki, M., Alizadehasl, A., Amin, A., Taghavi, S., Alemzadeh‐Ansari, M. J., Moussavi, A. K., & Naderi, N. (2017) · Journal of Cardiovascular and Thoracic Research · doi:10.15171/jcvtr.2017.17 · Cited by 15
Georgiopoulos, G. A., Tsioufis, C. P., Kalos, T., Magkas, N., Roussos, D., Chrysohoou, C. A., Sarri, G., Syrmali, K., Georgakopoulos, P., & Tousoulis, D. M. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161116666171226124959 · Cited by 15
Pavlušová, M., Jarkovský, J., Benešová, K., Vítovec, J., Linhart, A., Widimský, P., Špinarová, L., Zeman, K., Bělohlávek, J., Málek, F., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23197 · Cited by 15
Mechanisms of Disease: Is Mitochondrial Function Altered in Heart Failure?
Hamilton, D. J. (2013) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-9-1-44 · Cited by 15
Zong, Q., Ma, G., & Wang, T. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.13 · Cited by 14
Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis
Jamil, Y., Alameddine, D., Iskandarani, M. E., Agrawal, A., Arockiam, A. D., Haroun, E., Wassif, H. S., Collier, P., & Wang, T. K. M. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02138-y · Cited by 14
Biomarkers in Advanced Heart Failure: Diagnostic and Therapeutic Insights
Nagarajan, V., & Tang, W. H. W. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00244.x · Cited by 14
Singh, T. P., Skalina, T., Nour, D., Murali, A., Morrison, S., Moxon, J. V., & Golledge, J. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0881-6 · Cited by 14
Hatamizadeh, P. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.05.001 · Cited by 14
Pan, J., Lin, H., Wang, C., Zhang, J., & Gu, J. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01619-8 · Cited by 14
Maloberti, A., Colombo, V., Daus, F., Censi, L. D., Abrignani, M. G., Temporelli, P. L., Binaghi, G., Colivicchi, F., Grimaldi, M., Gabrielli, D., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103792 · Cited by 13
Igaki, Y., Tanno, M., Sato, T., Kouzu, H., Ogawa, T., Osanami, A., Yano, T., Kuno, A., Miki, T., Nakamura, T., et al. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.01.002 · Cited by 12
Sodium glucose co-transport 2 inhibitors for gout treatment
Somagutta, M. K. R., Luvsannyam, E., Jain, M. S., Cuddapah, G. V., Mustafa, N., Nasereldin, D. S., Pendyala, S. K., Jarapala, N., & PADAMATI, B. H. A. V. A. N. I. (2022) · Discoveries · doi:10.15190/d.2022.11 · Cited by 12
Ye, Y., Liao, G., Liu, T., Hu, X., Chen, X., Bai, L., & Peng, Y. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10090379 · Cited by 12
Documento de consenso para la detección y manejo de la enfermedad renal crónica
Martínez‐Castelao, A., Górriz, J. L., Bover, J., la Morena, J. S.-D., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., et al. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.09.001 · Cited by 13
Diagnostic and Prognostic Value of Uric Acid in Patients with Acute Dyspnea
Reichlin, T., Potocki, M., Breidthardt, T., Noveanu, M., Hartwiger, S., Burri, E., Klima, T. B., Stelzig, C., Laule, K., Mebazaa, A., et al. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.023 · Cited by 11
Liu, Y., & Peng, B. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.879354 · Cited by 11
Uric acid in advanced heart failure: relation to central haemodynamics and outcome
Deis, T., Rossing, K., Ersbøll, M. K., Wolsk, E., & Gustafsson, F. (2022) · Open Heart · doi:10.1136/openhrt-2022-002092 · Cited by 11
Tan, Z., Dai, T., Zhong, X., Tian, Y., Leppo, M. K., & Gao, W. D. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.033 · Cited by 11
Zhang, X., Lü, Q., Zhang, Z., Chen, Y., Wang, Y., Wang, Y., Zheng, L., & Jiang, L. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4132-0 · Cited by 11
Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes
Gaffo, A., & Saag, K. G. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11594580-000000000-00000 · Cited by 11
Damarla, M., Johnston, L., Liu, G. Y.-G., Gao, L., Wang, L., Varela, L., Kolb, T. M., Kim, B., Damico, R. L., & Hassoun, P. M. (2017) · Physiological Reports · doi:10.14814/phy2.13377 · Cited by 9
Oxypurinol protects renal ischemia/reperfusion injury via heme oxygenase-1 induction
Kang, H. B., Lim, C. K., Kim, J., & Han, S. J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1030577 · Cited by 10
The Relationship between Serum Uric Acid and Ejection Fraction of the Left Ventricle
Ivan, V. S., Buzaș, R., Morgovan, A., Ciubotaru, P. G., Ardelean, M., Goje, I.-D., Rosca, C. I., Timar, R. Z., & Lighezan, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10174026 · Cited by 10
Ivabradine for the treatment of chronic heart failure
Henri, C., O’Meara, E., de Denus, S., Elzir, L., & Tardif, J. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1165092 · Cited by 10
Perkutaner Aortenklappenersatz – Pro
Buellesfeld, L., & Grube, E. (2009) · Herz · doi:10.1007/s00059-009-3213-x · Cited by 10
Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies
Jiang, Y., Zhou, G., Guo, Y., & Long, Y. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0050 · Cited by 15
Vascular Consequences of Hyperuricemia and Hypouricemia
Albert, D., Scudder, P. N., Bagley, P. J., & Saag, K. G. (2019) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2019.04.005 · Cited by 9
He, Y., Feng, J., Zhang, B., Wu, Q., Zhou, Y., He, D., Zheng, D., & Yang, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1251451 · Cited by 12
Autophagy, Oxidative Stress, and Redox Regulation
Ma, J., Yang, L., Ren, J. T., & Yang, J. Z. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805253-2.00020-1 · Cited by 10
Youn, J. Y., Nguyen, A. H., & Cai, H. “. (2012) · Clinical Science · doi:10.1042/cs20110407 · Cited by 9
The Association Between Oxidative Stress and the Progression of Heart Failure: A Systematic Review
Chawla, H., Singh, N., & Singh, S. B. (2024) · Cureus · doi:10.7759/cureus.55313 · Cited by 8
Naegele, M., Flammer, A. J., Enseleit, F., & Ruschitzka, F. T. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14295 · Cited by 8
Treating Gout in Patients With Cardiovascular Disease
Givertz, M. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.006 · Cited by 8
Self-citationKodama, S., Fujihara, K., Horikawa, C., Yamada, M. H., Sato, T., Yaguchi, Y., Yamamoto, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07097-4 · Cited by 8
Zhang, J., Dierckx, R., & Cleland, J. G. F. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12059 · Cited by 8
Uric Acid, Oxidative Stress and Inflammation in Chronic Heart Failure with Reduced Ejection Fraction
Ilieșiu, A. M., Câmpeanu, A., Marta, D. S., Pârvu, I., & Gheorghe, G. S. (2015) · Revista română de medicină de laborator · doi:10.1515/rrlm-2015-0039 · Cited by 8
Yokota, T., Kinugawa, S., Fukushima, A., Okumura, T., Murohara, T., Tsutsui, H., & the LEAF-CHF Investigators (2024) · Heart and Vessels · doi:10.1007/s00380-024-02448-9 · Cited by 7
Etiology and pathogenesis of gout
McLean, L., & Becker, M. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00183-4 · Cited by 7
Kobalava, Z. D., & Троицкая, Е. А. (2021) · Kardiologiia · doi:10.18087/cardio.2020.12.n1158 · Cited by 7
Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights
Gulab, A., Torres, R., Pelayo, J., Lo, K. B., Shahzad, A., Pradhan, S., & Rangaswami, J. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1941873 · Cited by 7
Florea, V. G., & Anand, I. S. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2011.11.005 · Cited by 7
Hyperuricemia as a Risk Factor for Cardiovascular Diseases
Hisatome, I., Li, P., Taufiq, F., Maharani, N., Kuwabara, M., Ninomiya, H., & Bahrudin, U. (2020) · Journal of Biomedicine and Translational Research · doi:10.14710/jbtr.v6i3.9383 · Cited by 13
Tang, W. H. W. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.069 · Cited by 7
Incorporating Common Biomarkers into the Clinical Management of Heart Failure
Halkar, M. G., & Tang, W. H. W. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0165-5 · Cited by 6
Lee, J., Hu, Q., Mansoor, A., Kamdar, F. D., & Zhang, J. J. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9276-0 · Cited by 6
Neogi, T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2864-4.10019-3 · Cited by 6
Role of Oxidative Stress in the Pathophysiology of Arterial Hypertension and Heart Failure
Sousa, T., Reina‐Couto, M., & Gomes, P. (2019) · Springer eBooks · doi:10.1007/978-981-13-8273-4_23 · Cited by 6
Hyperuricemia and mortality in heart failure: Is it time to change the route?
Borghi, C., Cosentino, E. R., & Bragagni, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.01.005 · Cited by 6
Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
Cheng, C., Yen, C.-T., Su, C., Lee, C., Huang, C.-H., & Yang, Y. K. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.891606 · Cited by 5
Remodelling and adverse remodelling in CAD
Brenner, S., & Ertl, G. (2012) · Herz · doi:10.1007/s00059-012-3660-7 · Cited by 5
Novel treatments for diastolic heart failure
Nussinovitch, U., Topaz, G., Landesberg, A., & Feld, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813706-2.00006-3 · Cited by 5
Clinical Implication of Plasma Uric Acid Level
Shin, Y. T., Kim, K. K., & Hwang, I. C. (2009) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2009.30.9.670 · Cited by 5
Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit
DeFilippis, E. M., & Givertz, M. M. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0291-y · Cited by 5
Self-citationTang, W. H. W., & Francis, G. S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.026 · Cited by 5
McMurray, J. J. V., Petrie, M. C., Swedberg, K. B., Michel Komajda, N., Anker, S. D., & Gardner, R. S. (2009) · doi:10.1093/med/9780199566990.003.023 · Cited by 6
Habeeb, E. A., Ghaith, A. M., Alshehri, A. M., Aquil, G., Afana, A. H., Alqarafi, A. H., Alahmed, A. A., & Alkhezi, O. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1667438 · Cited by 4
Kang, E. H. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00986-3 · Cited by 6
Metadata
- Authors
- Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., Mann, D. L., Liu, P., Givertz, M. M., & Schwarz, R. P.
- Affiliations
- University of Miami (US)
- Cardiome (Canada) (CA)
- Rutgers, The State University of New Jersey (US)
- Boston University (US)
- Toronto General Hospital (CA)
- Brigham and Women's Hospital (US)
- Corresponding author
- Hare, Joshua M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2008-06
- Volume
- 51
- Issue
- 24
- Pages
- 2301-2309
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1414418298
- Cited by
- 392
- References
- 25
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 18 · 2023: 21 · 2022: 21 · 2021: 18 · 2020: 34 · 2019: 33 · 2018: 20 · 2017: 8 · 2016: 23 · 2015: 16 · 2014: 26 · 2013: 18 · 2012: 41
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- oxypurinol, xanthine oxidase inhibition, heart failure, systolic dysfunction, serum uric acid, hyperuricemia, biomarkers, quality of life
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Enzyme Inhibitors, Female, Health Status Indicators, Heart Failure, Humans, Male, Middle Aged, Oxypurinol, Quality of Life, Surveys and Questionnaires, Systole, Uric Acid, Xanthine Oxidase, Natriuretic Peptide, Brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
